ENZON PHARMACEUTICALS, INC.

Enzon Pharmaceuticals, Inc.

Biotechnology Healthcare Cranford, NJ, United States ENZN (OQB)

Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Biotechnology Companies

View All →

Frequently Asked Questions

Has ENZON PHARMACEUTICALS, INC. had layoffs?
No layoff events have been recorded for ENZON PHARMACEUTICALS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
What industry is ENZON PHARMACEUTICALS, INC. in?
ENZON PHARMACEUTICALS, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is ENZON PHARMACEUTICALS, INC. a publicly traded company?
Yes, ENZON PHARMACEUTICALS, INC. is publicly traded under the ticker symbol ENZN on the OQB. The company has a market capitalization of approximately $0.00 billion.
Where is ENZON PHARMACEUTICALS, INC. headquartered?
ENZON PHARMACEUTICALS, INC. is headquartered in Cranford, NJ, United States at 20 Commerce Drive, Cranford, NJ 07016, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.